511 Therapeutics, Inc.
Cambridge, MA
Funding event
The round itself, as filedInferred stagePre-seed
Sold of offered$500K of $1.0M
Filed2026-10-30
Days since filing14
- Exemption claimed
- Rule 506(b)
- First-ever Form D
- No
- Date of first sale
- 2026-10-21
Investors
No investors named: Form D does not list them
Officers on the filing
Names and roles as filed; addresses are never stored- Shuguang ZhangExecutive Officer · Director
- Yancen LuDirector
- Uwe B. SleytrDirector
- Andrew MarshallExecutive Officer · Director
Health flags
Three flags, each with the raw inputs behind it · as of 2026-11-13UndersubscribedNot flagged$500K of $1.0M sold0.8 months since first sale
Prior raiseNot flaggedRaised $500K against a prior $50K$50K prior raise, filed 2022-10-06
AmendedNot flaggedNo amendmentNo D/A on file
Open roles
On the employer's own careers page · check date not recorded0
Pre-posting windowNot enough dataShown once this sector and stage have 20 observed lags from filing to first posting.
No open roles foundWe read careers pages daily.
Also raised in Health & bio
Same sector, 28 days to 2026-11-15OrcosaSeries A · $6.0M of $11.5M · Ewing, NJQuietChronicleBioPre-seed · $250K of $1.0M · Menlo Park, CAQuiet
103 rounds in Health & bio in the 28 days to 2026-11-12, against 122 in the 28 days before.